NOTE: By submitting this form and registering with us, you are providing us with permission to store your personal data and the record of your registration. In addition, registration with the Medical Independent includes granting consent for the delivery of that additional professional content and targeted ads, and the cookies required to deliver same. View our Privacy Policy and Cookie Notice for further details.

You can opt out at anytime by visiting our cookie policy page. In line with the provisions of the GDPR, the provision of your personal data is a requirement necessary to enter into a contract. We must advise you at the point of collecting your personal data that it is a required field, and the consequences of not providing the personal data is that we cannot provide this service to you.

Don't have an account? Subscribe

ICS research head calls for further investigation following major prostate cancer screening study

By Mindo - 04th Dec 2019

The Head of Research for the Irish Cancer Society Dr Robert O’Connor has told this newspaper that further research is required after interim results from a long-term study evaluating the validity of targeted prostate-specific antigen (PSA) screening recommended that all men aged over 40 with the BRCA2 gene mutation are systematically screened for prostate cancer.

Dr Robert O’Connor

Presenting the interim IMPACT trial data at the recent Gathering around Cancer conference in Dublin, Prof Ros Eeles of the Institute of Cancer Research and the Royal Marsden NHS Trust, London, UK, said that their results found that men who carry the BRCA2 gene mutation are at risk of developing aggressive prostate cancer and so should undergo regular PSA testing.

The IMPACT study involved almost 3,000 men from 20 countries who were recruited from families that had carriers of mutations of the BRCA1 and BRCA2 genes and who underwent annual PSA testing and biopsy. Men who carried the BRCA2 mutations were almost twice as likely to develop prostate cancer than were non-carriers.

According to Prof Eeles, every man over the age of 40 who carries a mutation in the BRCA2 gene should be offered an annual PSA test – and it is hoped that this will be recommended in clinical guidelines in the near future.

The European Association of Urology guidelines committee is currently examining the issue.

Commenting on the IMPACT study results to the Medical Independent, Dr O’Connor said, although it has been known for some time that prostate cancer has genetic and familial associations, further study results examining the outcomes of such targeted screening in a real-world setting are required.

“Screening for prostate cancer is complex and not recommended for all men, such as it is for women in breast and cervical cancer,” according to Dr O’Connor.

“General population-level screening should only be carried out when we can do something with the results. This is relatively new research and it can take time for research to be turned into practice. Studies are ongoing currently to test the theory in a real-world setting.”

Leave a Reply

Latest Issue
The Medical Independent 20th February
The Medical Independent 20th February 2024

You need to be logged in to access this content. Please login or sign up using the links below.

Most Read